Philippe Camus, M.D.

Dijon, France

Both apps are now back!

Back to drug

The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

XLIII.a

Bronchospasm - Wheezing - Asthma

Publications

Goli AK, Osman MN, Koduri M, Byrd RP, Roy TM

A case report of vinorelbine monotherapy-related acute bronchospasm and non-ST elevation acute coronary syndrome.

Tennessee medicine : journal of the Tennessee Medical Association 2011 Jan;104;47-8 — 2011 Jan — 47-8

Kouroukis C, Hings I

Respiratory failure following vinorelbine tartrate infusion in a patient with non-small cell lung cancer.

Chest 1997 Sep;112;846-8 — 1997 Sep — 846-8

Hohneker JA

A summary of vinorelbine (Navelbine) safety data from North American clinical trials.

Seminars in oncology 1994 Oct;21;42-6; discussion 46-7 — 1994 Oct — 42-6; discussion 46-7